Development of a nomogram predicting metastatic disease and the assessment of NCCN, AUA and EAU guideline recommendations for bone imaging in prostate cancer patients - Takeaways - MDSpire

Development of a nomogram predicting metastatic disease and the assessment of NCCN, AUA and EAU guideline recommendations for bone imaging in prostate cancer patients

  • By

  • Ming-Wei Ma

  • Xian-Shu Gao

  • Feng Lyu

  • Xiao-Bin Gu

  • Huan Yin

  • Hong-Zhen Li

  • Xiao-Ying Li

  • Xin Qi

  • Yun Bai

  • Jia-Yan Chen

  • July 20, 2020

  • 0 min

Share

  • 1

    Prostate cancer (PCa) has high survival rates, but distant stage diagnosis significantly reduces five-year survival to 31%.

  • 2

    Bone is the primary site for PCa metastasis, necessitating careful monitoring for patients with unfavorable characteristics.

  • 3

    Current guidelines from NCCN, AUA, and EAU lack consensus on bone imaging recommendations for high-risk localized PCa patients.

  • 4

    This study utilized SEER data to analyze risk factors for PCa metastasis and developed nomograms to predict metastasis occurrence.

  • 5

    Guideline recommendations for bone imaging were assessed for sensitivity, specificity, and overall accuracy in identifying at-risk patients.

Original Source(s)

Development of a nomogram predicting metastatic disease and the assessment of NCCN, AUA and EAU guideline recommendations for bone imaging in prostate cancer patients

  • by Ming-Wei Ma, Xian-Shu Gao, Feng Lyu, Xiao-Bin Gu, Huan Yin, Hong-Zhen Li, Xiao-Ying Li, Xin Qi, Yun Bai, Jia-Yan Chen

  • July 20, 2020

Related Content

Does non-visible haematuria require urgent assessment? A retrospective cohort study from a university teaching hospital

Is it suitable to eliminate bone scan for prostate cancer patients with PSA ≤ 20 ng/mL?

Defining the role of multiparametric MRI in predicting prostate cancer extracapsular extension